Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25575996 | 0.84 | CRBN (0.50) | CRBNDDB1POLBHTTMAPT | |
| SCHEMBL25575916 | 0.82 | CRBN (0.61) | CRBNDDB1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL25920734 | 0.81 | CRBN (0.50) | CRBNDDB1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL25955979 | 0.80 | CRBN (0.52) | CRBNDDB1POLB | |
| SCHEMBL25905899 | 0.80 | CRBN (0.61) | CRBNDDB1POLB | |
| SCHEMBL25905901 | 0.79 | CRBN (0.49) | CRBNDDB1POLB | |
| SCHEMBL24204275 | 0.77 | CRBN (0.61) | CRBNDDB1POLB | |
| SCHEMBL25567472 | 0.76 | CRBN (0.52) | CRBNDDB1POLB | |
| SCHEMBL25929697 | 0.76 | CRBN (0.49) | CRBNDDB1POLB | |
| SCHEMBL25905904 | 0.76 | CRBN (0.46) | CRBNDDB1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | CRBN 221/4885DDB1 1973/4885POLB 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.